$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
克唑替尼治疗ALK阳性的非小细胞肺癌患者疗效显著
2025-10-19 11:44:20
Check Details
脑转移患者服用阿来替尼和克唑替尼那个疗效好?
2025-10-19 11:44:20
Check Details
色瑞替尼治疗ALK+阳性的NSCLC效果显著
2025-10-19 11:44:20
Check Details
克唑替尼ALK阳性非小细胞肺癌的一线治疗药物
2025-10-19 11:44:20
Check Details
一代药物耐药的肺癌患者可以选择阿法替尼
2025-10-19 11:44:20
Check Details
阿法替尼与吉非替尼治疗肺癌对比数据
2025-10-19 11:44:20
Check Details
色瑞替尼用于克唑替尼耐药肺癌患者
2025-10-19 11:44:20
Check Details
艾乐替尼治疗ALK阳性NSCNC患者
2025-10-19 11:44:20
Check Details
克唑替尼或第二代ALK抑制剂治疗ALK阳性肺癌患者
2025-10-19 11:44:20
Check Details
来那替尼联合坦西莫司治疗肺癌的效果
2025-10-19 11:44:20
Check Details
特罗凯和阿法替尼治疗肺鳞癌的数据
2025-10-19 11:44:20
Check Details
克唑替尼使中国肺癌患者获益
2025-10-19 11:44:20
Check Details
1
2
...
3015
3016
3017
3018
3019
3020
3021
...
4155
4156
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Onset Timeline and Efficacy Assessment of Margetuximab plus Chemotherapy in HER2-Positive Metastatic Breast Cancer
2
Avutometinib Plus Defactinib: A Precision Therapy for KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer
3
Vemurafenib (Zelboraf) Complete Medication Guide
4
Durvalumab Safety Profile: Managing Immune-Related Adverse Events (irAEs) in Clinical Practice
5
Zolbetuximab Combination Therapy: Global Efficacy and Safety Profile in CLDN18.2-Positive Advanced Gastric Cancer
6
Managing Mitotane Resistance in Adrenocortical Carcinoma: Strategies and Global Options
7
Trametinib & Dabrafenib in 2026: A Global Guide to Treating BRAF-Mutant Cancers
8
A Guide to Safely Stopping Mitotane: Why Tapering is Essential and How to Manage
9
Pemigatinib Efficacy: Significantly Improving Survival in FGFR2-Fusion Cholangiocarcinoma
10
Erlotinib: Targeting EGFR Mutations to Precisely Inhibit Non-Small Cell Lung Cancer Growth
11
Tofacitinib: The Role and Considerations of an Oral JAK Inhibitor in Autoimmune Disease Treatment
12
Tucatinib: Redefining the Treatment Landscape for HER2-Positive Cancers with High Selectivity